title: The effects of nitric oxide on the acquisition and expression of nicotine-induced conditioned place preference in mice.
abstract: In the present study, the possible role of nitric oxide on the conditioned place preference (CPP) induced by nicotine in mice was investigated. Intraperitoneal (i.p.) injections of nicotine (1 mg/kg) and the nitric oxide (NO) precursor, L-arginine (200 and 500 mg/kg), produced significant place preference. However, injection of mecamylamine (0.05 and 0.1 mg/kg; i.p.) or the NO synthase (NOS) inhibitor, L-Nitro-amino-methyl-ester, L-NAME (5-20 mg/kg; i.p.), had no effect. Ineffective doses of nicotine in combination with ineffective doses of L-arginine produced significant place preference. Administration of L-arginine (50, 100 and 150 mg/kg; i.p.) on the test day reduced the expression of nicotine-induced place preference. Nicotine injection (0.25, 0.5 and 0.75 mg/kg) on the test day reduced the expression of place preference induced by L-arginine, while both mecamylamine (0.05 and 0.1 mg/kg) and L-NAME (5, 10 and 20 mg/kg) inhibited the acquisition of place preference induced by nicotine (1 mg/kg) and L-arginine (200 mg/kg). Moreover, neither of the antagonists reduced the expression of nicotine- or L-arginine-induced place preference. It is suggested that nitric oxide may play an important role in nicotine-induced place preference.
authors.affiliation: Department of Physiology and Biophysics and Behavioral Sciences Research Center, Baghyatallah University of Medical Sciences, Iran.
authors.forename: Hedayat
authors.initials: H
authors.lastname: Sahraei
authors.forename: Mansour
authors.initials: M
authors.lastname: Falahi
authors.forename: Mohammad-Reaza
authors.initials: MR
authors.lastname: Zarrindast
authors.forename: Masoomeh
authors.initials: M
authors.lastname: Sabetkasaei
authors.forename: Hassan
authors.initials: H
authors.lastname: Ghoshooni
authors.forename: Mohsen
authors.initials: M
authors.lastname: Khalili
mesh_terms: D000818:Animals; D001120:Arginine / Q000494:pharmacology; D003216:Conditioning, Operant / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D051379:Mice; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism / Q000494:pharmacology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D012201:Reward; D014029:Tobacco Use Disorder / Q000523:psychology*; D014665:Vasodilator Agents / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D004791:Enzyme Inhibitors; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D014665:Vasodilator Agents; D009569:Nitric Oxide; D008464:Mecamylamine; D009538:Nicotine; D001120:Arginine; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester